Resetting the immune system
 through targeted delivery
 to APCs and T cells

Resetting the immune system
 through targeted delivery
 to APCs and T cells

Harnessing APCs and T Cells

Antigen-presenting cells (APCs) are the architects of the immune response by presenting antigens to T cells. Depending on how the antigen is presented, T cells can either become (a) pro-inflammatory “helper” CD4+ T cells or “killer” CD8+ T cells or (b) tolerogenic regulatory T cells (Tregs).

CD4+ T cells promote inflammaiton and help to active CD8+ T cells, which attack any cells presenting the corresponding antigens. Tregs, by contrast, reign in CD4+ and CD8+ T cells corresponding to specific antigens.

Antigen-Specific Immune Tolerance

BreezeBio’s lead programs induce immune tolerance. Non-immunogenic HNPs deliver mRNA encoding specific antigen(s) (with or without additional co-factors) to APCs. Presentation of antigens in the context of tolerance leads to unresponsive/anergic T cells and/or antigen-specific Tregs.

This approach has the potential to cure autoimmune diseases without broad immunosuppression, leaving the immune system otherwise intact to fight infections and malignancies.

BreezeBio’s differentiated approach

Unlike other immune tolerance approaches, BreezeBio’s platform technology features: 

  • Low Immunogenicity

    Low immunogenicity, which is essential for inducing tolerogenic immune responses

  • mRNA-Encoded Antigen Design

    mRNA encoding antigens to enable quick design and rapid indication expansion

  • Co-factor–Enabled Potency

    Inclusion of additional mRNA and/or small molecule co-factors to increase potency

In Vivo CAR-T

BreezeBio is leveraging our platform to re-engineer T cells directly in the body to generate reprogrammed CAR-T cells in vivo, which drives a stronger burst of efficacy for some forms of autoimmunity and cancer.

To treat autoimmune disease, in vivo CAR-T cells target B cells that produce autoantibodies. By transiently reducing the B cell population, the immune system is able to reset and restore homeostasis to spare healthy tissue.

BreezeBio’s differentiated approach

Compared to other approaches, BreezeBio’s technology features:

  • Accessible by Design

    Off-the-shelf technology to enable easy access

  • Simplified Manufacturing

    One-step formulation process in water to enable efficient manufacturing

  • Repeat-Dose Enabled

    Low immunogenicity to enable multiple doses

BreezeBio’s therapeutic programs apply targeted, programmable delivery to shape biological responses where precision matters most.

See Our Pipeline